A normal thyroid function is important for growth and neurological development in children, and hypothyroidism in childhood is accompanied by growth retardation. A growing number of reports have indicated that environmental chemicals can interfere with thyroid function \[reviewed by [@b6-ehp-118-1458]\]. Both experimental and observational studies of wildlife and humans have suggested specific chemicals to have thyroid-disrupting properties, including recent investigations of phthalates. Phthalates are widely used industrial chemicals that are applied in a large variety of commercial products---for example, as plasticizers in toys, personal care products, and building materials, including wall paint ([@b32-ehp-118-1458]; [@b33-ehp-118-1458]; [@b47-ehp-118-1458]). Thus, human exposure is extensive, as demonstrated in numerous studies by quantifying phthalate metabolites in urine samples from adults and children ([@b4-ehp-118-1458]; [@b28-ehp-118-1458]; [@b37-ehp-118-1458]). Most human studies have investigated reproductive effects of phthalate exposure, but recent studies also indicated thyroid-disrupting effects. Thus, serum levels of free thyroxine (T~4~) and total triiodothyronine (T~3~) in adult men were negatively associated with concentrations of metabolites of di(2-ethylhexyl) phthalate (DEHP) ([@b28-ehp-118-1458]). In pregnant women urinary concentrations of metabolites of di-*n*-butyl phthalate (DBP) were negatively correlated with serum levels of free and total T~4~ ([@b18-ehp-118-1458]).

The mechanisms of thyroid-disruption may be multiple, because experimental studies have suggested that phthalates interfere with binding of T~3~ to transport proteins ([@b21-ehp-118-1458]), interacting with the active T~3~ uptake at the plasma membrane ([@b36-ehp-118-1458]) or exerting antagonistic activity at the thyroid receptors ([@b35-ehp-118-1458]).

Phthalate exposure in children is probably higher than in adults when relating intake to body weight ([@b26-ehp-118-1458]). Furthermore, the adverse health outcomes due to environmental chemicals may be of greater significance in children because appropriate serum levels of thyroid hormone and insulin-like growth factor I (IGF-I) are significant for growth and neurological development. In a large cohort of children, we aimed to assess the exposure to six different diphthalates by measuring their metabolites in urine samples. Furthermore, we investigated the associations with growth and serum levels of thyroid hormones and IGF-I.

Materials and Methods
=====================

Study participants and design
-----------------------------

A total of 845 children 4--9 years of age were submitted to thorough clinical examinations between January 2006 and August 2007. All children had previously participated in a longitudinal cohort study, for which 1,953 women were included consecutively at their first routine obstetric control early in pregnancy at three university hospitals in Copenhagen, Denmark. Information regarding pregnancy and maternal health was obtained from medical records and questionnaires answered by the women. Gestational age of the newborn child was based on sonography, last menstrual period, and clinical evaluation of the newborn child. In case of discrepancies, sonography measurements were used. Details of the study have previously been published ([@b9-ehp-118-1458]). The children were examined shortly after birth and at 3, 18, and 36 months of age by standardized examinations. The length of the newborn child was measured supine with a Kiddimeter (Raven Equipment Ltd., Essex, UK) to the nearest 0.1 cm. All children participating up to 3 years of age (*n* = 1,440) were asked to participate in a follow-up study, 902 of whom consented. Of these, all children delivering a spot urine sample (*n* = 845) composed the present study population. The present study comprised measurements of height, weight, clinical assessment of pubertal stage (Tanner stage), ultrasound of the thyroid gland, including calculation of the gland volume (*n* = 839; [@b7-ehp-118-1458]), blood samples (*n* = 786), and spot urine samples. In addition, the parents filled in a questionnaire on health and lifestyle.

In the present study, we present information on phthalate exposure based on data from all children from whom urine samples had been collected. For the statistical analyses of associations between phthalate concentrations and growth or endocrine measures, we excluded all children suffering from diseases prone to affect growth or endocrine status as well as all children with clinical signs of puberty. Thus, a total of 26 children were excluded because of heart disease (*n* = 3), brain tumor (*n* = 1), Langerhans cell histiocytosis (*n* = 1), diabetes (*n* = 2), epilepsy (*n* = 3), cerebral palsy (*n* = 1), chronic gastrointestinal diseases (*n* = 2), juvenile arthritis (*n* = 1), pathological thyroid function tests \[two with thyroid-stimulating hormone (TSH) \> 3 SD, one with T~4~ \< 3 SD\], or puberty (*n* = 12).

Hormone analyses
----------------

Nonfasting peripheral venous blood samples were drawn from an antecubital vein between midmorning and late afternoon. Samples were separated by centrifugation and stored at −20°C until analyses. All analyses were carried out blinded for the technician and in random order.

TSH and thyroid hormones (T~4~, free T~4~, T~3~, and free T~3~) were measured with an electrochemiluminescence immunoassay (Modular Analytics E170; Roche GmbH, Mannheim, Germany). Total assay variations for TSH were 8.7% and 8.4% at concentrations of 0.9 and 4.9 mU/L, respectively; T~4~, 5.6% and 5.6% at 81 and 167 nmol/L; free T~4~, 6.0% and 8.1% at 12 and 30 pmol/L; T~3~, 6.7% and 6.6% at 3.2 and 6.0 nmol/L; and free T~3~, 6.4% and 6.4% at 5.3 and 15.0 pmol/L.

IGF-I and insulin-like growth factor binding protein 3 (IGFBP-3) were measured with solid-phase enzyme-labeled chemiluminescent immunometric assays (Immulite 2000; Diagnostic Products Corp., Los Angeles, CA, USA) using World Health Organization National Institute for Biological Standards and Control International Reference Reagent 87/518 and 93/560 standards, respectively. The limits of detection (LODs) were 20 and 0.1 μg/mL, respectively. Intraassay variations were \< 2.1% and 4.4%, respectively; and interassay variations were \< 8.9% and 5.6%, respectively.

Urinary phthalate metabolite analyses
-------------------------------------

Spot urine samples were collected in polyethylene cups and stored as 10-mL aliquots in 20-mL glass scintillation vials with tops packed with aluminum foil at −20°C. Urine samples were analyzed for concentrations of 12 different phthalate metabolites by liquid chromatography (LC) tandem mass spectrometry with preceding enzymatic deconjugation followed by solid phase extraction. The method for preparation of samples, standard solutions, and quality controls as well as the instrumental analysis was previously described ([@b22-ehp-118-1458]) and used with the following modifications. The solvents for LC separation were as follows: A, 0.1% acetic acid in water; B, 0.1% acetic acid in acetonitrile. Solvent programming was 0.0--1.5 min, 5% B; 1.6 min, 27% B; 6.0 min, 30% B; 6.1--10.0 min, 45% B; 10.1 min, 70% B; 12.0--15.5 min, 90% B; 15.6--17.0 min, 5% B. For all analytes, the retention time on column was 6.55--13.14 min, and a good separation was obtained. The precursor and product ions (*mz*) were as previously described ([@b38-ehp-118-1458]). The calibration curve range was 0.5--500 ng/mL. Method accuracy and precision were validated by repeating (*n* = 5) intraday analysis of pooled urine samples spiked with native phthalate standards (5, 10, and 50 ng/mL) and by repeating interday analysis of control urine samples spiked with low and high concentrations (*n* = 24 over a 2-month period). Mean (± SD) recovery ranged from 88% ± 8.6% to 108% ± 4.5%, and interday variation was \< 10% for most analytes. LODs were calculated as previously described ([@b5-ehp-118-1458]) and are listed in [Table 1](#t1-ehp-118-1458){ref-type="table"}. All urine samples with extremely high concentrations of phthalate metabolites were reanalyzed to confirm the values.

We analyzed the following metabolites: monoethyl phthalate (MEP) from diethyl phthalate (DEP); mono-*n*-butyl phthalate and monoisobutyl phthalate (MBP; analyzed as one compound) from di-*n*-butyl and DBP; monobenzyl phthalate (MBzP) from butyl benzyl phthalate; mono-(2-ethylhexyl) phthalate (MEHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), and mono(2-ethyl-5-carboxypentyl) phthalate (MECPP) from DEHP; mono-*n*-octyl phthalate (MOP) from di-*n*-octyl phthalate; and monoisononyl phthalate (MiNP) and monocarboxyisooctyl phthalate (MCiOP) from diisononyl phthalate (DiNP). In 250 randomly selected samples (125 girls, 125 boys), two additional secondary metabolites of DiNP were measured: monohydroxyisononyl phthalate (MHiNP) and monooxoisononyl phthalate (MOiNP). In samples from 100 randomly selected children, the content of both free and total (sum of free and conjugated) phthalate metabolites was determined, and the ratio was calculated (concentration of free/concentration of total phthalate metabolites).

Urinary iodine and creatinine analyses
--------------------------------------

Because low or high serum levels of iodine are known to affect thyroid function, the overall iodine status of the population was estimated by quantifying the iodine (^127^I) concentration in 250 randomly selected urine samples using an inductively coupled plasma mass spectrometer (Agilent Technologies, Waldbron, Germany) after dilution by an aqueous solution containing tetramethylammonium hydroxide. LOD was 0.1 μg/L. Recovery of iodine (mean ±SD) was 103 ± 3% (*n* = 13). Creatinine was determined in all urine samples by colorimetric enzymatic assay.

Statistical analyses
--------------------

Statistical analyses were performed with SPSS (version 17; SPSS, Inc., Chicago, IL, USA). Body surface area (BSA) was calculated using the DuBois formula: BSA (m^2^) = 0.007184 × height (cm)^0.725^ × weight (kg)^0.425^. Standard deviation scores (SDSs) of height, weight, body mass index (BMI), and BSA were calculated based on reference material from Danish children ([@b2-ehp-118-1458]; [@b29-ehp-118-1458]). Midparental height SDS (HSDS~midpar~) was calculated as the mean height SDS of both parents. To estimate the difference between expected and observed height, we also calculated the difference between child and midparental height SDS (DiffHSDS~midpar~), the change in height SDS between 0 and 3 years (ΔHSDS~0--3~) and between 1.5 years and the current examination (ΔHSDS~childhood~).

Log transformation was applied to phthalate concentrations, phthalate ratios, TSH, IGF-I, IGFBP-3, and thyroid volume to improve the approximation of normal distribution. Statistical analyses included only phthalate metabolites measurable in more than 50% of children. For phthalate metabolite levels below the LOD, LOD divided by the square root of 2 was used. We calculated the sum of concentrations of DEHP metabolites (MEHP, MEHHP, MEOHP, and MECPP, corrected for molecular weights). To estimate associations with the combined phthalate exposure, we calculated a total phthalate score: Concentrations of each of the metabolites MEP, MBP, MBzP, MCiOP, and the sum of DEHP metabolites were divided into quartiles, and the total phthalate score was the sum of quartiles 0--3 (range, 0--15). Because evidence on dose--response relationships between phthalates and thyroid hormone levels is sparse ([@b16-ehp-118-1458]; [@b30-ehp-118-1458]), the metabolites concerned were equally weighted in the calculation of the score.

We calculated the percentage of DEHP excreted as MEHP (MEHP%): MEHP concentration divided by the sum of all DEHP metabolite concentrations (MEHP, MEHHP, MEOHP, MECPP) × 100 (all concentrations were converted to nanomoles per milliliter). For samples with concentrations above LOD, the ratios between free and total metabolite concentrations were calculated.

We used parametric correlation analyses and the *t*-test to investigate associations between phthalate metabolite levels, age, body size, and SDS for anthropometric variables as well as sex differences. Multivariate linear regression was used to explore relationships between phthalate metabolite concentrations and serum hormone levels or growth estimates, including sex and age as covariates in analyses of hormone levels, and in addition HSDS~midpar~ and birth length in analyses of growth estimates.

Because urine was collected as spot samples, phthalate concentrations were adjusted for dilution by either dividing with the creatinine concentration or including the square root of creatinine concentrations in regression analyses. These two approaches yielded comparable estimates, so creatinine-corrected data represent phthalate divided by creatinine concentration. All statistical analyses were performed both with crude and creatinine-corrected phthalate concentrations. *p*-Values \< 0.05 were considered statistically significant.

Ethical aspects
---------------

Parents gave informed consent for the participation of their child. The study was performed according to the Helsinki II Declaration and was approved by the local ethics committee and the Danish Registry Agency.

Results
=======

Clinical characteristics of the 845 participating children are shown in [Table 2](#t2-ehp-118-1458){ref-type="table"}. All urine samples contained measurable amounts of metabolites of DEP, DBP, DEHP, and DiNP. Distributions of crude and creatinine-corrected concentrations of phthalate metabolites are presented in [Table 1](#t1-ehp-118-1458){ref-type="table"}. Crude concentrations of all phthalate metabolites were positively associated with each other, and creatinine-corrected concentrations also were positively associated with each other (*p* \< 0.01 in all cases). Samples from six children contained extremely high concentrations of MBP (one boy, 6,456 μg/L), MBzP (one boy, 4,547 μg/L), DEHP metabolites (MEHHP; one girl and one boy, 1,671--1,717 μg/L), or DiNP metabolites (two boys: MCiOP, 2,063 μg/L; MHiNP, 792 μg/L). Concentrations remained high after correcting for creatinine.

Boys presented significantly higher urine concentrations of MBzP, MEHP, MEHHP, MEOHP, and MCiOP (*p* \< 0.05 in all cases) than did girls. However, when corrected for creatinine, concentrations of MEP, MBP, and MECPP were higher in girls (*p* \< 0.05), whereas the concentrations of MBzP, MHiNP, and MCiOP remained highest in boys (*p* \< 0.05 in all cases). In correlation analyses, all phthalate metabolites were negatively associated with absolute values of height, weight, BMI, and BSA, reaching significance for MEP, MEOHP, MECPP, sum of DEHP metabolites, and total phthalate score (*r* = −0.097 to −0.074; *p* \< 0.05). Only MBzP was negatively (*r* = −0.077; *p* = 0.025) correlated with age. When corrected for creatinine, all phthalate metabolites were negatively correlated with age (*r* = −0.210 to −0.106; *p* \< 0.005 in all cases).

In the analyses of associations between phthalate concentrations and endocrine or growth measures, differences in results for boys and girls were generally within ranges consistent with random variation, but some estimates were statistically significant in only one group. In boys, phthalate metabolites were in general negatively associated with total and free T~3~, but few reached statistical significance ([Table 3](#t3-ehp-118-1458){ref-type="table"}) \[all confidence intervals are listed in Supplemental Material, Tables 1--3 (doi:10.1289/ehp.0901331)\]. However, associations became nonsignificant when correcting phthalate concentrations with creatinine. We found no consistent associations with TSH, T~4~, or free T~4~ (see Supplemental Material, Tables 1 and 2). IGF-I was negatively associated with crude DEHP metabolites and MCiOP ([Table 3](#t3-ehp-118-1458){ref-type="table"}, [Figure 1](#f1-ehp-118-1458){ref-type="fig"}), and IGFBP-3 with DEHP metabolites (*p* \< 0.05). We found significantly negative associations between recent height gain (ΔHSDS~childhood~) and both crude and creatinine-corrected DEHP metabolite concentrations (*p* \< 0.05) (see Supplemental Material, Table 3). All other associations between ΔHSDS~childhood~, IGF-I, IGFBP-3, and phthalate metabolites were similarly negative but not significantly. We found no consistent associations with current height (HSDS or DiffHSDS~midpar~).

In girls, all associations between peripheral thyroid hormones and unadjusted phthalate metabolites were negative, reaching significance for total T~3~ with most phthalate metabolites, for free T~3~ with MEP and DEHP metabolites ([Table 3](#t3-ehp-118-1458){ref-type="table"}), and for total T~4~ with MEP (B = −5.19, *p* = 0.013) and total phthalate score (B = −0.48, *p* = 0.037) \[Supplemental Material, Table 1 (doi:10.1289/ehp.0901331)\]. IGF-I was not significantly associated with unadjusted phthalate metabolites ([Table 3](#t3-ehp-118-1458){ref-type="table"}), but IGFBP-3 was significantly negatively associated with DEHP metabolites and MCiOP (*p* \< 0.05) (see Supplemental Material, Table 2). We found significantly negative correlations between current height (HSDS or DiffHSDS~midpar~) and most crude phthalate metabolites as well as the phthalate score (see Supplemental Material, Table 3). Early height gain (ΔHSDS~0--3~) was negatively associated with MCiOP. When correcting for creatinine, only a few associations with thyroid hormones remained significant. For growth estimates, most significant associations became nonsignificant, whereas several associations with recent height gain (ΔHSDS~childhood~) became significant (see Supplemental Material, Table 3).

When analyzing boys and girls together, unadjusted phthalate metabolites showed significant negative associations with T~3~, free T~3~, and IGF-I ([Figures 1](#f1-ehp-118-1458){ref-type="fig"} and [2](#f2-ehp-118-1458){ref-type="fig"}, [Table 3](#t3-ehp-118-1458){ref-type="table"}). The associations with IGF-I, but not with thyroid hormones, remained significant after correction for urinary creatinine \[Supplemental Material, Figure 1 (doi:10.1289/ehp.0901331)\]. Current growth measures (HSDS, DiffHSDS~midpar~ and ΔHSDS~childhood~) were significantly negatively associated with most DEHP metabolites and their sum, for both crude and creatinine-corrected concentrations (see also Supplemental Material, Table 3). Thyroid volume ranged from 1.0 to 6.8 mL and demonstrated no statistically significant sex difference. In neither boys nor girls was thyroid volume SDS associated with concentrations of phthalate metabolites (data not shown).

Mean ± SD MEHP% was 5.9 ± 2.7%. MEHP% was positively correlated with weight (*r* = 0.072, *p* = 0.039) and BSA (*r* = 0.072, *p* = 0.040) and negatively associated with T~4~ (*r* = −0.077, *p* = 0.034) and creatinine (*r* = −0.141, *p* \< 0.001). Median ratios between free and total phthalate metabolite concentrations ranged from \< 0.1 (MBP, MEHHP, MEOHP, MHiNP) to 0.6--0.8 (MEP, MECPP, MCiOP). Ratios correlated positively with each other (*p* ≤ 0.001 in all cases) and negatively with age (significant for MEP, MEOHP, and MHiNP) and body size.

Urinary concentration of creatinine was significantly positively associated with age, height, weight, and BSA (*p* ≤ 0.001 in all cases), and boys had higher levels of urinary creatinine than did girls (*p* = 0.001). Seventy-three urine samples were very dilute, with a creatinine concentration \< 0.2 g/L. When excluding these samples from the statistical analyses, most associations between phthalate metabolites and total and free T~3~ became insignificant, although they remained negative (data not shown).

Median iodine concentration was 192.0 μg/L (282.3 μg I/g creatinine), and the 20th percentile was 115.9 μg/L. Thus, the subgroup of children tested was iodine sufficient according to World Health Organization criteria ([@b46-ehp-118-1458]). We repeated all the above analyses with inclusion of children with diseases or with exclusion of children born prematurely (*n* = 54) or small for gestational age (*n* = 40) and children with extremely high urinary concentrations of phthalate metabolites (*n* = 6). This did not change the overall pattern of associations. In extended versions of the regression analyses demonstrated in [Table 3](#t3-ehp-118-1458){ref-type="table"}, we added interaction variables between phthalate metabolites and sex. In these analyses, associations between hormone levels and both phthalate levels and the interaction variable were generally nonsignificant, suggesting that estimates for boys and girls combined were valid estimates of effect and that the differences in estimates that we observed between boys and girls were generally consistent with random variation. However, we cannot rule out sex-specific effects in our study population because we had limited power to assess them. Phthalate concentrations in samples from the three excluded children with aberrant thyroid hormone concentrations were within the observed ranges in the rest of the children.

Discussion
==========

In this comprehensive study of phthalate exposure and health effects in children, we determined urinary excretion of 12 phthalate metabolites in 845 iodine-sufficient Danish children 4--9 years of age and related phthalate exposure measures to thyroid function and growth. The concentrations of phthalate metabolites were largely comparable to levels previously reported from other studies of children ([@b4-ehp-118-1458]; [@b26-ehp-118-1458]; [@b32-ehp-118-1458]; [@b37-ehp-118-1458]; [@b45-ehp-118-1458]), except for relatively low levels of MEP: The geometric mean of MEP in our study group was 21 μg/L, in contrast to 91 and 177 μg/L in American studies of children ([@b37-ehp-118-1458]; [@b41-ehp-118-1458]). Levels of MBP were higher in Danish children than in studies from the United States ([@b32-ehp-118-1458]; [@b37-ehp-118-1458]; [@b45-ehp-118-1458]) but comparable to levels in young adults in Sweden ([@b23-ehp-118-1458]) and children in Germany ([@b26-ehp-118-1458]). This may indicate regional differences in exposure.

Overall, urinary phthalate concentrations were negatively associated with thyroid hormones and IGF-I as well as with childhood growth. In some cases results were statistically significant in girls but not in boys, or vice versa. In girls, crude concentrations of phthalate metabolites were negatively associated with total and free T~3~, thus potentially reflecting an effect of phthalates on thyroid function. In boys, these associations were not as consistent, although the overall trend was also negative. Adverse effects of phthalates on peripheral thyroid hormones are supported by results from two other epidemiological studies ([@b18-ehp-118-1458]; [@b28-ehp-118-1458]). Thus, a study of pregnant women found an inverse association between MBP and T~4~ and free T~4~ ([@b18-ehp-118-1458]), whereas a study of adult men reported negative associations between MEHP and free T~4~ and T~3~ ([@b28-ehp-118-1458]). Evidence from animal studies is sparse, but in rats exposed to DBP ([@b30-ehp-118-1458]) and DEHP ([@b16-ehp-118-1458]) peripheral thyroid hormones were reduced, and several studies found reduced thyroid weight and histopathology indicating thyroid hyperactivity (smaller follicles, increased number, size, and iodine content of lysosomes) after phthalate exposure ([@b17-ehp-118-1458]; [@b31-ehp-118-1458]). However, in view of the very complex and multifactorial regulation of thyroid size ([@b13-ehp-118-1458]), it is not surprising that the changes in phthalate concentrations were not reflected by thyroid size alterations in our population.

Our results also revealed associations of phthalates with IGF-I in children. Few previous studies have directly addressed the effect of endocrine-disrupting chemicals on the growth hormone (GH)/IGF-I axis. Studies of IGF-I effects indicated that prenatal exposure to DBP or DEHP may lead to induction of IGF-I mRNA in reproductive tissues ([@b8-ehp-118-1458]; [@b27-ehp-118-1458]), reflecting a lowering of IGF-I levels. Additionally, phthalates may potentially interact with other endocrine pathways, such as the hypothalamic--pituitary axis or androgen biosynthesis. Such complex *in vivo* effects might be expected to contribute to differences in effects according to sex. Antiandrogenic drugs may reduce IGF-I ([@b25-ehp-118-1458]), and because studies have shown phthalates to have antiandrogenic properties ([@b12-ehp-118-1458]), phthalates may consequently interfere with IGF-I levels. Moreover, the GH/IGF-I axis is known to stimulate the activity of peripheral deiodinases, converting T~4~ to the biologically active T~3~ ([@b19-ehp-118-1458]; [@b24-ehp-118-1458]). Thus, an effect on IGF-I may indirectly reduce serum levels of T~3~.

Growth rate and anthropometric measurements such as height, weight, and BSA showed overall negative associations with urinary concentrations of phthalate metabolites, consistent with an adverse effect of phthalates on growth. In support, animal studies have shown negative associations between prenatal phthalate exposure and birth weight ([@b40-ehp-118-1458]; [@b42-ehp-118-1458]) as well as gain of body weight ([@b11-ehp-118-1458]), although conflicting data have been reported ([@b3-ehp-118-1458]; [@b34-ehp-118-1458]). In contrast to these studies, and to the common hypothesis of phthalates causing impaired fetal growth, [@b44-ehp-118-1458] showed a positive association between phthalates of low molecular weight and duration of pregnancy and infant head circumference.

In our comprehensive study, we performed numerous association tests between a large number of outcome measures and 12 different phthalate metabolites. Clearly, such multiple significance testing implies a risk of obtaining "false-positive" results by chance. We therefore focused our interpretation of the results on overall trends and not on single significant associations. Thyroid hormones and growth factors are closely linked with each other and contribute significantly in the regulation of childhood growth. Thus, our observation of associations between phthalate exposure and growth supports the conclusion that phthalate exposure in this age group exerts an adverse biological effect.

However, words of caution appear necessary with regard to assessment of phthalate exposure. We collected spot urine samples, the concentrations of which will depend on recent fluid intake. Previous reports have attempted to correct, at least partly, for dilution by measuring urinary creatinine concentrations or specific gravity. However, the excretion of creatinine in children is strongly correlated with age and anthropometric variables as height, weight, and BSA ([@b39-ehp-118-1458]), as also seen in our study. In addition, there is a sex difference, with boys having higher excretion of creatinine compared with girls ([@b39-ehp-118-1458]). Thus, sex and anthropometric features per se may affect the level of the correction factor (creatinine). Consequently, when correcting phthalate concentrations by dividing by creatinine, corrected phthalate values will tend to decrease with age and body size, thus mimicking a negative association between phthalate levels and growth parameters. Such an interaction has also been demonstrated in a study of maternal urinary phthalate levels and the associations with infant outcome ([@b44-ehp-118-1458]). In contrast, associations with parameters declining with age, such as peripheral thyroid hormones in childhood, will tend to become more positive, which may be the case for the associations seen with thyroid hormones in our study.

Not only creatinine but also renal glomerular filtration rate and thus urinary volume are influenced by age, anthropometry, thyroid hormones ([@b20-ehp-118-1458]), and IGF-I ([@b10-ehp-118-1458]). Thus, large and fast-growing children with high levels of thyroid hormones and IGF-I have a higher probability of large urinary volumes and consequently lower crude urinary concentrations of phthalate metabolites than do small children being exposed to the same amount of phthalates. Furthermore, small children may be exposed to higher levels of phthalates relative to body size ([@b43-ehp-118-1458]), because small children have a higher food intake as well as a higher body surface per kilogram of body weight. Hence, the negative associations between urinary phthalate concentrations and body size or height gain may partly be explained by physiological mechanisms resulting in reverse causality. In order to adjust for the interaction between creatinine and outcome, other studies ([@b1-ehp-118-1458]) included the square root of creatinine. However, in our study, the application of this correction modus did not significantly change the statistical estimates and overall results.

Reservations should also be stated in relation to the fact that we collected only a single urine sample from each child, which may not be representative for their average exposure, although several studies concluded that a single urine sample could be moderately predictive of individual exposure over a couple of months ([@b15-ehp-118-1458]; [@b41-ehp-118-1458]).

One previous study suggested that MEHP% may be a phenotypic marker of DEHP metabolism and excretion ([@b14-ehp-118-1458]; [@b28-ehp-118-1458]). MEHP% was positively associated, and the fraction of free phthalate metabolites negatively associated, with age and anthropometric measurements, so it seems that age and body size may affect phthalate metabolism, both oxidation and glucuronidation. Other studies have found similar relations between hydrolyzed and oxidized metabolites ([@b4-ehp-118-1458]). Interestingly, MEHP% was negatively associated with T~4~ in our material, which has also been reported in a previous study ([@b28-ehp-118-1458]). Thus, thyroid hormones may have an accelerating effect on the metabolism of phthalates.

Conclusions
===========

Our study showed negative associations between urinary phthalate concentrations and thyroid hormones, IGF-I, and growth in healthy children. Although our study was not designed to reveal the mechanism of action, the overall coherent negative associations between urine phthalate and thyroid and growth parameters may suggest causative negative roles of phthalate exposures for child health.
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Sex-specific phthalate metabolite concentrations (μg/L and μg/g creatinine) in spot urine samples from 845 Danish children 4--9 years of age (examined 2006--2007).

  Phthalate metabolite                                   LOD    Percent \> LOD   Male   Female                                                            
  ------------------------------------------------------ ------ ---------------- ------ -------- ------ ----- ----- ------- ----- ----- ----- ----- ----- -------
  Uncorrected concentration (μg/L)                                                                                                                        
   MEP                                                   0.24   100              21     21       0.6    11    39    731     21    21    1.1   10    44    684
   MBP                                                   3.94   100              130    124      12     75    207   6,457   121   114   9.0   63    216   1,217
   MBzP                                                  1.26   86               17     2.8      0.0    6.2   37    4,548   12    0.5   0.0   3.3   31    272
   MEHP                                                  0.31   99               4.5    4.1      0.0    2.5   7.7   78      3.6   3.6   0.0   1.8   7.2   231
   MEHHP                                                 0.60   100              37     33.2     1.0    19    64    1,718   31    28    1.3   14    55    1,672
   MEOHP                                                 0.14   100              19     17       0.5    9.6   32    656     16    15    0.6   7.8   29    734
   MECPP                                                 0.43   100              30     29       1.0    16    52    676     27    27    1.7   14    49    1,755
   MOP                                                   0.04   16               0.0    0.0      0.0    0.0   0.0   11      0.0   0.0   0.0   0.0   0.0   11
   MiNP                                                  0.62   49               0.6    1.1      0.0    0.0   1.8   1,100   0.5   1.1   0.0   0.0   1.7   61
   MHiNP[a](#tfn2-ehp-118-1458){ref-type="table-fn"}     0.31   98               6.6    5.8      0.1    3.3   11    793     4.9   4.5   0.0   2.1   8.2   400
   MOiNP[a](#tfn2-ehp-118-1458){ref-type="table-fn"}     0.16   99               3.4    2.9      0.0    1.7   5.1   312     2.7   2.3   0.1   1.3   4.1   188
   MCiOP                                                 0.08   100              7.2    7.3      0.3    4.1   12    2,063   6.5   6.3   0.3   3.5   12    598
                                                                                                                                                          
  Creatinine-corrected concentration (μg/g creatinine)                                                                                                    
   MEP                                                                           31     34       5.7    20    52    791     36    40    7.6   22    65    526
   MBP                                                                           191    199      47.5   140   276   4,940   227   221   39    157   312   1,365
   MBzP                                                                          26     25       0.0    10    49    2,916   20    22    0.0   6.9   42    474
   MEHP                                                                          6.8    6.9      0.0    4.1   11    210     6.7   7.2   0.0   4.1   12    186
   MEHHP                                                                         52     53       4.9    33    84    1,818   52    55    7.3   36    81    1,220
   MEOHP                                                                         26     27       2.6    17    42    794     28    29    3.5   18    41    536
   MECPP                                                                         43     46       6.5    29    68    1,648   49    51    8.2   33    75    1,280
   MOP                                                                           0.0    0.0      0.0    0.0   0.0   10      0.0   0.0   0.0   0.0   0.0   11
   MiNP                                                                          1.0    1.7      0.0    0.0   2.7   1,194   1.1   2.0   0.0   0.0   3.3   45
   MHiNP[a](#tfn2-ehp-118-1458){ref-type="table-fn"}                             8.4    8.9      1.6    5.5   14    754     7.4   7.6   0.0   4.9   9.9   292
   MOiNP[a](#tfn2-ehp-118-1458){ref-type="table-fn"}                             4.1    4.4      0.0    2.8   6.2   296     3.9   3.9   0.2   2.6   5.2   137
   MCiOP                                                                         10     12       1.9    6.9   18    2,241   12    12    1.4   7.5   18    574

Abbreviations: 25%, 25th percentile; 75%, 75th percentile; GM, geometric mean; Max, maximum; Min, minimum.

Measured in only 250 randomly selected samples.

###### 

Clinical characteristics of the population \[mean ± SD or *n* (%)\].

  Characteristic                               Total (*n* = 845)   Males (*n* = 503)   Females (*n* = 342)
  -------------------------------------------- ------------------- ------------------- ---------------------
  Age (years)                                  7.0 ± 1.3           6.9 ± 1.4           7.1 ± 1.1
  Birth weight (kg)                            3.5 ± 0.6           3.6 ± 0.6           3.5 ± 0.6
  Birth length (cm)                            50.8 ± 2.6          51.2 ± 2.6          50.4 ± 2.5
  Gestational age (days)                       278.8 ± 13.2        279.2 ± 12.6        278.3 ± 14.0
  WGA (%)                                      −0.6 ± 12.9         −0.8 ± 12.7         −0.2 ± 13.3
  Height (cm)                                  124.5 ± 9.5         124.4 ± 10.1        124.7 ± 8.6
  Weight (kg)                                  24.7 ± 5.4          24.6 ± 5.6          24.9 ± 4.9
  BMI (kg/m^2^)                                15.8 ± 1.7          15.7 ± 1.6          15.9 ± 1.8
  BSA (m^2^)                                   0.9 ± 0.1           0.9 ± 0.1           0.9 ± 0.1
  Thyroid volume (mL)                          3.1 ± 1.0           3.1 ± 1.1           3.1 ± 0.9
  Urinary creatinine (g/L)                     0.7 ± 0.4           0.7 ± 0.4           0.7 ± 0.4
  Urinary iodine (μg/L)                        216.4 ± 126.6       232.6 ± 131.5       200.4 ± 119.9
  Corrected urinary iodine (μg/g creatinine)   328.7 ± 177.7       337.8 ± 178.2       319.7 ± 177.5
  Maternal parity \[*n* (%)\]                                                          
   1                                           524 (62)            317 (63)            207 (61)
   2                                           247 (29)            143 (28)            104 (31)
   \> 2                                        72 (9)              43 (9)              29 (8)
  Outcome                                                                              
   Singletons                                  803 (95)            478 (95)            325 (95)
   Twins                                       42 (5)              25 (5)              17 (5)

WGA, weight for gestational age, given as percent deviation from expected mean weight for gestational age.

###### 

Regression analyses (adjusted for age and sex) of associations between phthalate metabolites and total T~3~, free T~3~, and IGF-I in prepubertal Danish children (*n* = 758).

                    Crude analysis   Creatinine-corrected analysis                                                                                                                                                                                                                                                                                    
  ----------------- ---------------- ---------------------------------------------------- ------- ---------------------------------------------------- ------- ---------------------------------------------------- ------- ---------------------------------------------------- ------- ---------------------------------------------------- ------- ----------------------------------------------------
  Total T~3~                                                                                                                                                                                                                                                                                                                                          
  MEP               −0.06            0.015[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.01   0.829                                                −0.12   0.001[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.02   0.605                                                0.05    0.262                                                −0.11   0.026[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}
  MBP               −0.09            0.005[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.06   0.143                                                −0.14   0.007[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.01   0.873                                                −0.01   0.875                                                −0.02   0.780
  MBzP              −0.05            0.016[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.04   0.150                                                −0.06   0.041[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.03   0.266                                                −0.03   0.412                                                −0.03   0.436
  MCiOP             −0.07            0.017[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.07   0.060                                                −0.06   0.142                                                −0.01   0.837                                                −0.04   0.347                                                0.06    0.345
  ∑DEHP             −0.04            0.170                                                0.00    0.950                                                −0.10   0.022[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   0.06    0.153                                                0.09    0.082                                                0.00    0.965
  Phthalate score   −0.01            0.018[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   0.00    0.518                                                −0.01   0.003[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   0.00    0.769                                                0.00    0.630                                                0.00    0.773
                                                                                                                                                                                                                                                                                                                                                      
  Free T~3~                                                                                                                                                                                                                                                                                                                                           
  MEP               −0.13            0.013[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.08   0.253                                                −0.18   0.013[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   0.00    0.986                                                0.10    0.310                                                −0.14   0.179
  MBP               −0.21            0.002[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.26   0.004[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.15   0.141                                                0.03    0.785                                                −0.09   0.517                                                0.15    0.325
  MBzP              −0.08            0.032[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.08   0.137                                                −0.09   0.120                                                −0.02   0.710                                                −0.01   0.883                                                −0.03   0.643
  MCiOP             −0.18            0.002[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.21   0.005[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.12   0.144                                                −0.04   0.580                                                −0.09   0.300                                                0.06    0.648
  ∑DEHP             −0.15            0.011[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.13   0.107                                                −0.19   0.030[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   0.04    0.626                                                0.08    0.460                                                −0.05   0.689
  Phthalate score   −0.01            0.006[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.01   0.061                                                −0.02   0.038[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   0.00    0.562                                                0.00    0.844                                                0.00    0.662
                                                                                                                                                                                                                                                                                                                                                      
  IGF-I                                                                                                                                                                                                                                                                                                                                               
  MEP               −0.01            0.213                                                −0.01   0.479                                                −0.02   0.292                                                −0.01   0.559                                                0.00    0.921                                                −0.02   0.309
  MBP               −0.01            0.671                                                −0.01   0.536                                                0.00    0.961                                                0.02    0.336                                                0.02    0.574                                                0.03    0.427
  MBzP              −0.01            0.383                                                −0.02   0.170                                                0.00    0.796                                                0.00    0.737                                                −0.01   0.321                                                0.01    0.510
  MCiOP             −0.04            0.003[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.04   0.006[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.03   0.153                                                −0.04   0.006[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.05   0.020[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.04   0.137
  ∑DEHP             −0.03            0.014[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.05   0.002[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   0.00    0.816                                                −0.04   0.034[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   −0.07   0.003[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   0.01    0.798
  Phthalate score   0.00             0.027[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   0.00    0.011[\*](#tfn5-ehp-118-1458){ref-type="table-fn"}   0.00    0.639                                                0.00    0.307                                                0.00    0.106                                                0.00    0.769

Abbreviations: B, regression coefficient; ∑DEHP, sum of concentrations of all measured DEHP metabolites corrected for molecular weights.

*p* \< 0.05.
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